Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review Bristol-Myers Squibb Business and Pfizer Inc. today announced that the U cyclophosphamide side effect .S. The Prescription Drug Consumer Fee Act goal date for a decision by the FDA is definitely March 15, 2014. Related StoriesMayo Clinic hospitals generate top-tier Large Performing distinction in U.S. News & World Survey ratingsColorado PERA now offers new hip and knee alternative benefit option for retirees in pre-Medicare programLower socioeconomic position significantly increases risk of pain following knee replacement The ADVANCE-1 supports The submission, ADVANCE-2, and ADVANCE-3 medical trials, part of the EXPANSE clinical trial program.
Net revenue in the first nine months of 2007 on a GAAP basis had been $2.3 billion, or $1.14 per diluted share, compared to $1.7 billion, or $0.88 per diluted talk about for the same period this past year. On a non-GAAP basis, excluding specified items, Bristol-Myers Squibb reported net revenue of $2.2 billion, or $1.september 30 13 per diluted share for the nine months ended, 2007, in comparison to $1.8 billion, or $0.89 per diluted share for the same period this past year. For more info, visit About Bristol-Myers Squibb Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.